This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05434/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/drug/DB05434/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05434/identifier/bindingdb/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05434/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05434/identifier/drugbank/

Statements

Subject Item
n2:DB05434
rdf:type
n3:Drug
n3:description
ABT-510 is peptide mimetics of thrombospondin-1 (TSP-1), block angiogenesis in vitro and in vivo and slow tumor growth. It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
n3:generalReferences
# Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C: Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res. 2006 Dec 15;12(24):7444-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17189418 # Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ, Loos WJ, Knight RA, Carr RA, Humerickhouse RA, Eskens FA: A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol. 2006 Aug;17(8):1320-7. Epub 2006 May 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16728485
n3:group
investigational
n3:indication
Investigated for use/treatment in lymphoma (unspecified), melanoma, and solid tumors.
owl:sameAs
n13:DB05434
dcterms:title
ABT-510
adms:identifier
n6:6918562 n7:ABT-510 n8:5293759 n9:DB05434 n11:50165195
n3:mechanismOfAction
ABT-510 is a synthetic peptide that mimics the anti-angiogenic activity of the naturally occurring protein, thrombospondin-1 (TSP-1). Angiogenesis is the process of new blood vessel formation. ABT-510 blocks the actions of multiple pro-angiogenic growth factors known to play a role in cancer related blood vessel growth, such as VEGF, bFGF, HGF, and IL-8. ABT-510 is the first compound with this mechanism of action to be studied.
n3:IUPAC-Name
n4:271B438A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4390-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B438F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B438C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B438D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B438E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4388-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4389-363D-11E5-9242-09173F13E4C5 n4:271B4386-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4387-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4396-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4397-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4391-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4392-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4394-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4393-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4395-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B439C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B439E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B439F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B439B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B439A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B439D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B438B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4398-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4399-363D-11E5-9242-09173F13E4C5